Celldex Therapeutics, Inc.
CLDX
$32.43
$0.431.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -58.59% | -63.91% | -45.73% | -32.88% | -23.45% |
| Total Depreciation and Amortization | 3.00% | 6.39% | 8.53% | 7.97% | 6.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.09% | 64.10% | 68.03% | 51.64% | 17.23% |
| Change in Net Operating Assets | 252.89% | 165.08% | 153.76% | -295.06% | -542.31% |
| Cash from Operations | -29.53% | -33.70% | -13.71% | -53.25% | -43.69% |
| Capital Expenditure | -122.17% | -41.43% | -19.68% | -59.20% | -16.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 246.82% | 173.48% | 137.20% | 132.10% | 114.80% |
| Cash from Investing | 250.19% | 172.06% | 136.61% | 131.57% | 114.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -54.63% | -99.46% | -99.78% | -99.71% | -99.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -54.63% | -99.46% | -99.78% | -99.71% | -99.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.98% | 107.97% | -102.37% | -235.69% | -260.68% |